BIOCON.NS - Biocon Limited

NSE - NSE Real Time Price. Currency in INR
401.85
+6.25 (+1.58%)
At close: 3:30PM IST
Stock chart is not supported by your current browser
Previous close395.60
Open399.05
Bid401.85 x 0
Ask0.00 x 0
Day's range392.65 - 406.35
52-week range211.05 - 410.45
Volume4,989,273
Avg. volume7,746,990
Market cap482.16B
Beta (5Y monthly)0.60
PE ratio (TTM)63.79
EPS (TTM)6.30
Earnings date23-Jul-2020
Forward dividend & yield0.50 (0.13%)
Ex-dividend date18-Jul-2019
1y target est650.36
  • Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus
    Motley Fool

    Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus

    Here's some welcome news for diabetics dealing with the high price of insulin: The Food and Drug Administration has approved Mylan (NASDAQ: MYL) and Biocon's Semglee, which is essentially identical to Sanofi's (NASDAQ: SNY) insulin product Lantus. The companies didn't disclose what they plan to charge for Semglee when announcing the approval, but Mylan CEO Heather Bresch implied that it would be cheaper than Lantus. The opportunity for Mylan and Biocon (which bills itself as India's largest biopharmaceutical) is substantial; IQVIA estimates that Sanofi took in $1.68 billion in revenue from Lantus vials and $4.33 billion from the Lantus SoloSTAR Pen in the 12-month period that ended in April.

  • Sensex, Nifty hit four-month low as virus outbreak fans pandemic fears
    Reuters

    Sensex, Nifty hit four-month low as virus outbreak fans pandemic fears

    Indian stocks ended lower for a fifth straight day on Thursday after hitting four-month lows, as fears of the coronavirus becoming a pandemic made investors flee riskier assets. The broader NSE Nifty 50 index fell 0.4% to 11,633.30, while the benchmark S&P BSE Sensex declined 0.4% to 39,732.93. Governments ramped up measures on Thursday to battle a looming global pandemic of the coronavirus as the number of infections outside China, the source of the outbreak, for the first time surpassed those appearing inside the country.

  • GlobeNewswire

    Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand

    Equillium Inc. (EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, and Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced that they have expanded their collaboration and license agreement for itolizumab to grant Equillium exclusive rights for developing and commercializing itolizumab in Australia and New Zealand. Equillium had originally secured exclusive rights to develop and commercialize Biocon’s novel biologic, itolizumab, for the U.S. and Canada markets, in May 2017.

  • Coffee baron's death fuels India Inc anger over govt crackdown on wrongdoing
    Reuters

    Coffee baron's death fuels India Inc anger over govt crackdown on wrongdoing

    The apparent suicide of India's coffee baron V.G. Siddhartha, under investigation by tax authorities, has inflamed anger towards the government among business leaders who feel it is going too far in its crackdown on fraud and tax evasion. Drastic measures taken by Prime Minister Narendra Modi's administration include stringent action to enforce tax compliance, probes into bank lending practices and threatening auditors with five-year bans for alleged lapses in their work.

  • Coffee baron's death fuels India Inc anger over government crackdown on wrongdoing
    Reuters

    Coffee baron's death fuels India Inc anger over government crackdown on wrongdoing

    The apparent suicide of India's coffee baron V.G. Siddhartha, under investigation by tax authorities, has inflamed anger towards the government among business leaders who feel it is going too far in its crackdown on fraud and tax evasion. Drastic measures taken by Prime Minister Narendra Modi's administration include stringent action to enforce tax compliance, probes into bank lending practices and threatening auditors with five-year bans for alleged lapses in their work.